Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE Response to consultation
DATE 2019-05-24
TOPICS Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE: Response to consultation
DATE: 2019-02-20
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE       Response to consultation
DATE              2018-12-04
TOPICS            Pharmaceuticals, prescribing, cannabis, drugs
                        Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE  Response to consultation
DATE  2018-10-02
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-09-06</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety</td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE
Response to consultation

DATE
2018-08-14

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA response:
HEALTH CANADA CONSULTATION ON REGULATORY AMENDMENTS REGARDING TRAMADOL

August 14, 2018
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE  Response to consultation
DATE  2018-07-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE  
Response to consultation

DATE  
2018-01-19

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents
**Excise duty framework for cannabis products**

https://policybase.cma.ca/link/policy13799

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2017-12-07</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**

![CMA Submission: Excise Duty Framework for Cannabis Products]

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE  Response to consultation
DATE  2017-11-7
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
Consultation on the renewal of Federal Tobacco Control Strategy

https://policybase.cma.ca/link/policy13804

POLICY TYPE  
Response to consultation

DATE  
2017-04-05

TOPICS  
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

MAY 1, 2017

COMMISSIONERS OF THE FEDERAL TOBACCO CONTROL PROGRAM

Chair, Interim

Martin Wenitsyn, MD

Northwest Territories, Yukon, Nunavut

Chair, Steering Committee

Susan MacKie, MD

Newfoundland and Labrador

Chair, Tobacco Control Program

Graham Aylward, MD

Canada Health Assembly

In consultation with the Federal Tobacco Control Strategy

The Canadian Medical Association (CMA) is requesting your input for the consultation and analysis of the Federal Tobacco Control Strategy (FTCS), and on the development of the Renewal of Tobacco Control Strategy in Canada. We are pleased to invite you to provide your comments.

The results of the Canadian Lung Health Alliance's (CLHA) 2016 Tobacco Control Strategic Review, titled "Protecting the Next Generation: Defining Canada's National Tobacco Control Strategy for the Decade 2017-2026," have been submitted to Health Canada. The CLHA Review provides an evidence-based framework to guide innovation and investment in tobacco control initiatives.

The CMA believes that stronger measures are needed to reduce smoking prevalence among youth and adults, prevent new tobacco users from becoming addicted, and support the transition to a smoke-free population in Canada. This will require renewed investment in evidence-based tobacco control initiatives, including funding for health research and clinical trials, development of new policies and regulations, and enhanced public awareness and education campaigns.

We encourage you to provide your feedback on the consultation and analysis of the Federal Tobacco Control Strategy, and on the development of the Renewal of Tobacco Control Strategy in Canada. We look forward to hearing your thoughts and working together to achieve a smoke-free society in Canada.

Sincerely,

The Canadian Medical Association
Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE
Response to consultation

DATE
2016-10-31

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE  Response to consultation
DATE           2016-08-29
TOPICS         Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana Legalization and Regulation

August 29, 2016

STATEMENT  |  DÉCLARATION

Chief Statement - Application of Evidence

Evidence, September 9, 2016 - The CMA's submission to the Task Force on Marijuana Legalization and Regulation highlighted that the current state of knowledge regarding marijuana and its role in society is not adequate. The Task Force must take this into account when making recommendations.

The CMA strongly supports the elimination of marijuana’s illegal status and calls for a public health approach.

The CMA strongly supports the elimination of marijuana's illegal status and calls for a public health approach.

The Task Force's recommendations on marijuana should be evidence-based and take into account the impact on public health, public safety, and the economy.

As per the CMA's recommendations, the Task Force should consider the following recommendations for the legalization of marijuana.

1. The Task Force should consider the introduction of a public health approach to marijuana legalization.

2. The Task Force should consider the introduction of a public health approach to marijuana legalization.

3. The Task Force should consider the introduction of a public health approach to marijuana legalization.

4. The Task Force should consider the introduction of a public health approach to marijuana legalization.

5. The Task Force should consider the introduction of a public health approach to marijuana legalization.

6. The Task Force should consider the introduction of a public health approach to marijuana legalization.

7. The Task Force should consider the introduction of a public health approach to marijuana legalization.

8. The Task Force should consider the introduction of a public health approach to marijuana legalization.

9. The Task Force should consider the introduction of a public health approach to marijuana legalization.

10. The Task Force should consider the introduction of a public health approach to marijuana legalization.

11. The Task Force should consider the introduction of a public health approach to marijuana legalization.

12. The Task Force should consider the introduction of a public health approach to marijuana legalization.

For further information, please contact: info@cma.ca

Adaptation onריח: CMA 2016-08-29

CMA Policybase - Canadian Medical Association
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

August 12, 2016
Dr. D. Taylor
Chief, Policy Topics
Canadian Medical Association
700 Laurier Avenue West
Ottawa, ON K1R 7C6

Dear Dr. Taylor,

The Canadian Medical Association (CMA) is pleased to provide its submission to the Health Canada Consultation on “Plain and Standardized Packaging.”

The CMA calls on the federal government to continue to build on its current framework of plain and standardized packaging by implementing a ban on designer packaging for prescription medications.

The CMA submits this response to the consultation as a follow-up to the release of its position paper on plain and standardized packaging in June 2016.

CMA’s position paper on plain and standardized packaging was developed in consultation with CMA’s Sections, Council, and Committee on Public Health, as well as the College of Family Physicians of Canada, the Canadian Pharmacists Association, the Canadian Pharmacists Association—Ontario, the Canadian Society of Hospital Pharmacists, and the Canadian Association of Law enforcement and Criminal Justice.

The CMA supports the federal government’s efforts to improve health outcomes and reduce the harm caused by drug misuse and addiction. The Ottawa-Carleton Drug Policy Board’s 2016 report “Addressing the Opioid Crisis in Ottawa” highlighted the importance of plain and standardized packaging in reducing the risk of drug misuse and overdose.

The CMA also supports the federal government’s efforts to reduce the burden of prescription drug misuse and addiction by implementing plain and standardized packaging. The CMA believes that plain and standardized packaging would help to reduce the number of drug-related deaths and reduce the costs associated with drug misuse and addiction.

The CMA recommends that the federal government consider implementing plain and standardized packaging for all prescription medications, including over-the-counter medications.

The CMA also recommends that the federal government consider implementing plain and standardized packaging for all prescription medications, including over-the-counter medications.

The CMA believes that plain and standardized packaging would help to reduce the number of drug-related deaths and reduce the costs associated with drug misuse and addiction.

Thank you for considering CMA’s submission.

Yours sincerely,

[Signatures]

Canadian Medical Association

[Page numbers]

CMA Policybase - Canadian Medical Association p. 16
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE: Response to consultation
DATE: 2016-03-19
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE  Response to consultation
DATE  2016-01-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE  Response to consultation
DATE  2015-06-08
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

POLICY TYPE
Response to consultation

DATE
2014-08-26

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents